Clinical Trials Logo

Filter by:
NCT ID: NCT02614261 Completed - Chronic Migraine Clinical Trials

Evaluation of Galcanezumab in the Prevention of Chronic Migraine

REGAIN
Start date: November 30, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.

NCT ID: NCT02614196 Completed - Migraine Clinical Trials

Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study

EVOLVE-2
Start date: December 4, 2015
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.

NCT ID: NCT02613494 Completed - Sialorrhea Clinical Trials

Clozapine-induced Hypersalivation - Feasibility Trial

GOTHIC1
Start date: January 25, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

A randomised placebo-controlled feasibility study of glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation to assess recruitment and retention rates in a multi-centre trial.

NCT ID: NCT02612857 Completed - Dermatomyositis Clinical Trials

Trial of IMO-8400 in Adult Patients With Dermatomyositis

8400-211
Start date: November 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis.

NCT ID: NCT02612532 Completed - Lung Cancer Clinical Trials

Lung Cancer Indicator Detection

LuCID
Start date: October 7, 2015
Phase: N/A
Study type: Interventional

The Lung Cancer Indicator Detection (LuCID) study investigates the the diagnostic accuracy of FAIMS for diagnosis of lung cancer by analysis of exhaled Volatile Organic Compounds.

NCT ID: NCT02612415 Completed - Hypoxia Clinical Trials

FIRST-line Support for Assistance in Breathing in Children (FIRST-ABC) Feasibility Study

FIRST-ABC
Start date: November 2015
Phase: Phase 2/Phase 3
Study type: Interventional

A feasibility study to inform the design and conduct of a randomised controlled trial of high flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in critically ill children

NCT ID: NCT02612233 Completed - Hand Osteoarthritis Clinical Trials

Pain Management in Osteoarthritis Using the Centrally Acting Analgesics Duloxetine and Pregabalin

DUPRO
Start date: September 2013
Phase: Phase 4
Study type: Interventional

Osteoarthritis is the most common form of arthritis worldwide. Specifically, osteoarthritis of the hands affects millions of people and is a major cause of hand disability and pain. Despite this, there are currently no treatments that delay or halt the development of osteoarthritis. Pain is one of the major symptoms of osteoarthritis and pain management is an important factor to consider in the treatment of this condition. Treatments for pain in osteoarthritis consists of local injections, anti-inflammatory gels or painkillers such as paracetamol. However, most people with osteoarthritis still have pain despite these treatments.

NCT ID: NCT02612168 Completed - Malignant Melanoma Clinical Trials

Melanoma Image Analysis Algorithm (MIAA) Validation Study

Start date: January 11, 2017
Phase: N/A
Study type: Interventional

Prospective, single-arm, cross-sectional, study to establish the effectiveness of MIAA to detect melanoma in pigmented lesions, compared to gold standard histological determination.

NCT ID: NCT02612064 Completed - Dentin Sensitivity Clinical Trials

The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity

Start date: November 2015
Phase: N/A
Study type: Interventional

This single centre, dual site, comparative design study will be used to investigate the efficacy of an experimental stannous fluoride containing dentifrice in relieving dentinal hypersensitivity (DH) after short term use

NCT ID: NCT02612051 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients

Start date: December 4, 2015
Phase: Phase 1
Study type: Interventional

GSK3008348 is an investigational drug, being developed by GlaxoSmithKline Research and Development Limited (the Sponsor, a pharmaceutical company based in the UK) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a rare and poorly understood disease that causes scarring of the lungs. The main symptoms are shortness of breath and a dry cough. Symptoms generally worsen over time and in some subjects may prove fatal. The cause of IPF is unknown. This is a First Time in Human, Phase 1, 3-part study which is being carried out on behalf of the Sponsor by Quintiles. The primary purpose of Part A is to examine the safety and tolerability of single nebulised (a medicated spray) doses of GSK3008348 following inhalation in healthy volunteers. The secondary objective is to determine how and at what rate the body absorbs, distributes, breaksdown and eliminates the drug. Parts B and C of this study will be in-patients with Idiopathic Pulmonary Fibrosis (IPF). The purpose of Part B and C is to examine the safety and tolerability, and how much of the drug binds to its target, following single nebulised (a medicated spray) doses of GSK3008348 following inhalation in patients with Idiopathic Pulmonary Fibrosis (IPF). The secondary objective is to determine how and at what rate the bodies of these patients absorbs, distributes, breaksdown and eliminates the drug. The total duration of Part A will be 65 - 87 days, Part B 62 days and Part C 43 days.